Financial Contrast: Nyxoah (NASDAQ:NYXH) vs. Health Catalyst (NASDAQ:HCAT)

Health Catalyst (NASDAQ:HCAT) and Nyxoah (NASDAQ:NYXH) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, profitability, dividends, earnings and analyst recommendations.

Profitability

This table compares Health Catalyst and Nyxoah’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Health Catalyst	-87.69%	-3.52%	-1.77%
Nyxoah	-543.21%	-163.73%	-80.24%

Risk and Volatility

Health Catalyst has a beta of 1.56, meaning that its share price is 56% more volatile than the S&P 500. Comparatively, Nyxoah has a beta of 1.61, meaning that its share price is 61% more volatile than the S&P 500.

Insider and Institutional Ownership

85.0% of Health Catalyst shares are owned by institutional investors. 19.4% of Health Catalyst shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares Health Catalyst and Nyxoah”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Health Catalyst	$302.48 million	0.52	-$177.97 million	($3.72)	-0.58
Nyxoah	$15.33 million	3.64	-$101.92 million	($2.48)	-0.58

Nyxoah has lower revenue, but higher earnings than Health Catalyst. Nyxoah is trading at a lower price-to-earnings ratio than Health Catalyst, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current ratings and target prices for Health Catalyst and Nyxoah, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Health Catalyst	1	8	4	0	2.23
Nyxoah	1	1	2	0	2.25

Health Catalyst currently has a consensus price target of $2.93, suggesting a potential upside of 36.68%. Nyxoah has a consensus price target of $5.96, suggesting a potential upside of 314.06%. Given Nyxoah’s stronger consensus rating and higher possible upside, analysts plainly believe Nyxoah is more favorable than Health Catalyst.

Summary

Health Catalyst beats Nyxoah on 8 of the 14 factors compared between the two stocks.

About Health Catalyst

Health Catalyst, Inc. provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases. It offers services expertise solutions comprising data and analytics, domain expertise and education, tech-enabled managed, and implementation services; and opportunity analysis and prioritization, data governance, data modeling and analysis, quality and process improvement strategy, cost accounting, data abstraction, and population health strategies. The company was formerly known as HQC Holdings, Inc. and changed its name to Health Catalyst, Inc. in March 2017. Health Catalyst, Inc. was founded in 2008 and is headquartered in South Jordan, Utah.

About Nyxoah

Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company’s lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah S.A. was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.